ZDHHC20

Across TCGA pan-cancer cohorts, ZDHHC20 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ZDHHC20’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ZDHHC20 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZDHHC20 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

PDAC, COAD, and CCRCC are the cancer types where ZDHHC20 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZDHHC20 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	+0.401	.002	5	view →
COAD	Male	All	+0.285	.005	4	view →
CCRCC	All	All	+0.224	.001	2	view →
LUAD	Male	All	−0.121	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ZDHHC20–PDAC

Open the PDAC breakdown →